Nektar Therapeutics (NKTR) Interest Expenses (2010 - 2026)

Nektar Therapeutics' Interest Expenses history runs 17 years deep, the most recent figure standing at $7.9 million for Q1 2026.

• On a quarterly basis, Interest Expenses rose 59.67% year-over-year to $7.9 million in Q1 2026; TTM through Mar 2026 was $29.2 million, a 5.8% increase from a year earlier, with the FY2025 full-year figure at $892.4 million, up 3.88% from the prior year.
• Interest Expenses fell to $7.9 million in Q1 2026 per NKTR's latest filing, from $9.8 million in the prior quarter.
• Across five years, Interest Expenses topped out at $10.2 million in Q4 2024 and bottomed at $5.0 million in Q1 2025.
• The 5-year median for Interest Expenses is $6.4 million (2024), against an average of $6.9 million.
• Biggest YoY gain for Interest Expenses was 132.17% in 2022; the steepest drop was 45.68% in 2022.
• Year by year, Interest Expenses stood at $7.2 million in 2022, then slipped by 4.64% to $6.9 million in 2023, then soared by 47.85% to $10.2 million in 2024, then dropped by 3.78% to $9.8 million in 2025, then declined by 18.7% to $7.9 million in 2026.
• Per Business Quant, the three latest NKTR Interest Expenses figures stand at $7.9 million (Q1 2026), $9.8 million (Q4 2025), and $6.0 million (Q3 2025).